Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

R. Buhl; D. Berdel; C.-P. Criée; A. Gillissen; P. Kardos; C. Kroegel; W. Leupold; H. Lindemann; H. Magnussen; D. Nowak; D. Pfeiffer-Kascha; K. Rabe; M. Rolke; G. Schultze-Werninghaus; H. Sitter; D. Ukena; C. Vogelmeier; T. Welte; R. Wettengel; H. Worth

doi:10.1055/s-2005-919153

Pneumologie 2006; 60(3): e1-e45
DOI: 10.1055/s-2005-919153

Leitlinie

Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma

Herausgegeben von der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.Guidelines for Diagnosis and Treatment of Asthma PatientsGerman Airway League and German Respiratory SocietyR. Buhl¹ , D. Berdel¹ , C.-P. Criée¹ , A. Gillissen¹ , P. Kardos¹ , C. Kroegel¹ , W. Leupold¹ , H. Lindemann¹ , H. Magnussen¹ , D. Nowak¹ , D. Pfeiffer-Kascha¹ , K. Rabe¹ , M. Rolke¹ , G. Schultze-Werninghaus¹ , H. Sitter¹ , D. Ukena¹ , C. Vogelmeier¹ , T. Welte¹ , R. Wettengel¹ , H. Worth¹

¹Schwerpunkt Pneumologie, III. Medizinische Klinik, Mainz

Abstract

Full Text

References

Literatur

1 Global Initiative for Asthma (GINA) .NHLBI/WHO workshop report. National Heart, Lung and Blood Institute, National Institutes of Health. Bethesda, Md., www.ginasthma.com updated October 2005
2 Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. Br Med J. 2001; 323 334-336
3 Harju T, Keistinen T, Tuuponen T. et al . Seasonal variation in childhood asthma hospitalisations in Finland, 1972 - 1992. Eur J Pediatr. 1997; 156 436-439
4 Mitakakis T Z, Tovey E R, Xuan W. et al . Personal exposure to allergenic pollen and mould spores in inland New South Wales, Australia. Clin Exp Allergy. 2000; 30 1733-1739
5 O'Hollaren M T, Yunginger J W, Offord K P. et al . Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med. 1991; 324 359-363
6 Gibson P G, Dolovich J, Denburg J. et al . Chronic cough: eosinophilic bronchitis without asthma. Lancet. 1989; 1 1346-1348
7 Corrao W M, Braman S S, Irwin R S. Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med. 1979; 300 633-637
8 Irwin R S, Curley F J, French C L. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis. 1990; 141 640-647
9 Kardos P, Cegla U, Gillissen A. et al . Leitlinie der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit akutem und chronischem Husten. Pneumologie. 2004; 58 570-602
10 Fujimura M, Ogawa H, Nishizawa Y. et al . Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma?. Thorax. 2003; 58 14-18
11 Dow L. Asthma in older people. Clin Exp Allergy. 1998; 28 Suppl 5 195-202
12 Weiner P, Magadle R, Waizman J. et al . Characteristics of asthma in the elderly. Eur Respir J. 1998; 12 564-568
13 Morris M J. Difficulties with diagnosing asthma in the elderly. Chest. 1999; 116 591-593
14 Quadrelli S A, Roncoroni A J. Is asthma in the elderly really different?. Respiration. 1998; 65 347-353
15 Burrows B, Halonen M, Barbee R A. et al . The relationship of serum immunoglobulin E to cigarette smoking. Am Rev Respir Dis. 1981; 124 523-525
16 Tracey M, Villar A, Dow L. et al . The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV₁. A longitudinal study in the elderly. Am J Respir Crit Care Med. 1995; 151 656-662
17 Kroegel C, Mock B, Machnik A. et al . Medikamenten-induziertes Churg-Strauss-Syndrom: Eine neue Krankheitsentität?. Arzneimitteltherapie. 2001; 19 285-295
18 Mutius E von, Martinez F D, Fritzsch C. et al . Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med. 1994; 149 358-364
19 Beasley R, Keil U, Mutius E von. et al . Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet. 1998; 351 1225-1232
20 Nowak D, Heinrich J, Jorres R. et al . Prevalence of respiratory symptoms, bronchial hyperresponsiveness and atopy among adults: West and East Germany. Eur Respir J. 1996; 9 2541-2552
21 Heinrich J, Richter K, Frye C. et al . Die europäische Studie zu Atemwegserkrankungen bei Erwachsenen [European Community Respiratory Health Survey in Adults (ECRHS)]. Pneumologie. 2002; 56 297-303
22 Nowak D, Suppli U C, Mutius E. Asthma and atopy: has peak prevalence been reached?. Eur Respir J. 2004; 23 359-360
23 Nowak D, Mutius E von. Asthma bronchiale im Kindes- und Erwachsenenalter: Risikofaktoren, Diagnose, Standardtherapie. Dtsch Med Wochenschr. 2004; 129 509-516
24 Chinn S, Jarvis D, Burney P. et al . Increase in diagnosed asthma but not in symptoms in the European Community Respiratory Health Survey. Thorax. 2004; 59 646-651
25 Braun-Fahrlander C, Gassner M, Grize L. et al . No further increase in asthma, hay fever and atopic sensitisation in adolescents living in Switzerland. Eur Respir J. 2004; 23 407-413
26 Akinbami L J, Schoendorf K C. Trends in childhood asthma: prevalence, health care utilization, and mortality. Pediatrics. 2002; 110 315-322
27 Ronchetti R, Villa M P, Barreto M. et al . Is the increase in childhood asthma coming to an end? Findings from three surveys of schoolchildren in Rome, Italy. Eur Respir J. 2001; 17 881-886
28 Kalyoncu A F, Selcuk Z T, Enunlu T. et al . Prevalence of asthma and allergic diseases in primary school children in Ankara, Turkey: two cross-sectional studies, five years apart. Pediatr Allergy Immunol. 1999; 10 261-265
29 Fleming D M, Sunderland R, Cross K W. et al . Declining incidence of episodes of asthma: a study of trends in new episodes presenting to general practitioners in the period 1989 - 98. Thorax. 2000; 55 657-661
30 Verlato G, Corsico A, Villani S. et al . Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol. 2003; 111 1232-1238
31 Weiland S K, Pearce N. Asthma prevalence in adults: good news?. Thorax. 2004; 59 637-638
32 Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol. 2001; 107 937-944
33 Nowak D, Volmer T, Wettengel R. Asthma bronchiale - eine Krankheitskostenanalyse. Pneumologie. 1996; 50 364-371
34 Schramm B, Ehlken B, Smala A. et al . Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J. 2003; 21 116-122
35 Bousquet J, Jeffery P K, Busse W W. et al . Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161 1720-1745
36 Jones P W. Quality of life measurement in asthma. Eur Respir J. 1995; 8 885-887
37 Ryan G, Latimer K M, Dolovich J. et al . Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator, and airway calibre. Thorax. 1982; 37 423-429
38 O'Byrne P, Cuddy L, Taylor D W. et al . The clinical efficacy and cost benefit of inhaled corticosteroids as therapy in patients with mild asthma in primary care practice. Can Respir J. 1996; 3 169-175
39 Essen-Zandvliet E E, Hughes M D, Waalkens H J. et al . Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis. 1992; 146 547-554
40 Criée C-P, Berdel D, Heise D. et al .Empfehlungen der Deutschen Atemwegsliga zur Spirometrie. München - Orlando: Dustri-Verlag Dr. Karl Feistle 2006: 1-17
41 American Thoracic Society . Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med. 1995; 152 1107-1136
42 European Respiratory Society . Standardized lung function testing. Eur Respir J Suppl. 1993; 16 1-100
43 American Thoracic Society . Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991; 144 1202-1218
44 Tattersfield A E, Postma D S, Barnes P J. et al . Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med. 1999; 160 594-599
45 Gibson P G, Wong B J, Hepperle M J. et al . A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy. 1992; 22 525-532
46 Kendrick A H, Higgs C M, Whitfield M J. et al . Accuracy of perception of severity of asthma: patients treated in general practice. Br Med J. 1993; 307 422-424
47 Killian K J, Watson R, Otis J. et al . Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med. 2000; 162 490-496
48 Nowak R M, Pensler M I, Sarkar D D. et al . Comparison of peak expiratory flow and FEV₁ admission criteria for acute bronchial asthma. Ann Emerg Med. 1982; 11 64-69
49 Quanjer P H, Lebowitz M D, Gregg I. et al . Peak expiratory flow: conclusions and recommendations of a Working Party of the European Respiratory Society. Eur Respir J Suppl. 1997; 24 2S-8S
50 Sawyer G, Miles J, Lewis S. et al . Classification of asthma severity: should the international guidelines be changed?. Clin Exp Allergy. 1998; 28 1565-1570
51 Reddel H K, Marks G B, Jenkins C R. When can personal best peak flow be determined for asthma action plans?. Thorax. 2004; 59 922-924
52 D'Souza W J, Te K H, Fox C. et al . Long-term reduction in asthma morbidity following an asthma self-management programme. Eur Respir J. 1998; 11 611-616
53 Venables K M, Chan-Yeung M. Occupational asthma. Lancet. 1997; 349 1465-1469
54 Quackenboss J J, Lebowitz M D, Krzyzanowski M. The normal range of diurnal changes in peak expiratory flow rates. Relationship to symptoms and respiratory disease. Am Rev Respir Dis. 1991; 143 323-330
55 Reddel H K, Salome C M, Peat J K. et al . Which index of peak expiratory flow is most useful in the management of stable asthma?. Am J Respir Crit Care Med. 1995; 151 1320-1325
56 Kamps A W, Roorda R J, Brand P L. Peak flow diaries in childhood asthma are unreliable. Thorax. 2001; 56 180-182
57 Lebowitz M D. The use of peak expiratory flow rate measurements in respiratory disease. Pediatr Pulmonol. 1991; 11 166-174
58 Niggemann B, Friedrichs F, Brosi W. et al . Arbeitsgemeinschaft Lungenfunktion der Gesellschaft für Pädiatrische Pneumologie: Unspezifische Provokationsverfahren in der pneumologischen Diagnostik. Monatsschr Kinderheilkd. 1999; 147 601-609
59 Lindemann H, Leupold W. Bronchiale Provokation. Lungenfunktonsdiagnostik bei Kindern. Stuttgart: Kohlhammer 2003: 162-173
60 Lindemann H, Leupold W. Lungenfunktionsdiagnostik im frühen Kindesalter. Lungenfunktonsdiagnostik bei Kindern. Stuttgart: Kohlhammer 2003: 174-193
61 O'Byrne P. Bronchial challenges by pharmacological agents. In: Clark TJH, Godfrey S, Lee TH, Thomson NC (Hrsg). Asthma. London: Arnold 2000: 92-103
62 Leitlinien für die Durchführung bronchialer Provokationstests mit pharmakologischen Substanzen. Pneumologie. 1998; 52 214-220
63 Ramsdale E H, Morris M M, Roberts R S. et al . Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol. 1985; 75 573-577
64 Haren E H van, Lammers J W, Festen J. et al . The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med. 1995; 89 209-214
65 Ramsdale E H, Morris M M, Roberts R S. et al . Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax. 1984; 39 912-918
66 Matthys H, Hamm H. Bronchial challenge tests: different answers due to differences in site and magnitude of airway obstruction. In: Oehling AK, Huerta Lopez JG (Hrsg). Progress in Allergy and Clinical Immunology. Volume 4, Cancun. Berlin-Toronto-Bern-Göttingen: Hogrefe & Huber 1997: 263-268
67 Brooks L J, Cloutier M M, Afshani E. Significance of roentgenographic abnormalities in children hospitalized for asthma. Chest. 1982; 82 315-318
68 Gershel J C, Goldman H S, Stein R E. et al . The usefulness of chest radiographs in first asthma attacks. N Engl J Med. 1983; 309 336-339
69 Pizzichini M M, Popov T A, Efthimiadis A. et al . Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med. 1996; 154 866-869
70 Kharitonov S, Alving K, Barnes P J. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J. 1997; 10 1683-1693
71 Horvath I, Barnes P J. Exhaled monoxides in asymptomatic atopic subjects. Clin Exp Allergy. 1999; 29 1276-1280
72 Mok Q, Piesowicz A T. Foreign body aspiration mimicking asthma. Intensive Care Med. 1993; 19 240-241
73 Place R, Morrison A, Arce E. Vocal cord dysfunction. J Adolesc Health. 2000; 27 125-129
74 Kardos P, Brutsche M, Buhl R. et al . Sowohl Asthma, als auch COPD: Eine Kombination beider Erkrankungen. Pneumologie. 2006 (im Druck);
75 Lenney W. The burden of pediatric asthma. Pediatr Pulmonol. 1997; 15 Suppl 13-16
76 Juniper E F. Quality of life in adults and children with asthma and rhinitis. Allergy. 1997; 52 971-977
77 Rabe K F, Vermeire P A, Soriano J B. et al . Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000; 16 802-807
78 Juniper E F, Guyatt G H, Ferrie P J. et al . Measuring quality of life in asthma. Am Rev Respir Dis. 1993; 147 832-838
79 Juniper E F, Buist A S, Cox F M. et al . Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999; 115 1265-1270
80 Hyland M E. The Living with Asthma Questionnaire. Respir Med. 1991; 85 Suppl B 13-16
81 Mühlig S. Diagnostik und Beurteilung der psychischen Leistungsfähigkeit von Atemwegserkrankten. In: Petro W (Hrsg). Pneumologische Prävention und Rehabilitation. Berlin: Springer 2000: 316-332
82 Schandry R, Duschek S. Fragebogen für Asthma-Patienten. In: Schumacher J, Klaiberg A, Brähler E (Hrsg). Diagnostische Verfahren zu Lebensqualität und Wohlbefinden. Göttingen: Hogrefe-Verlag 2003: 111-115
83 Mühlig S, Teeling H, Petermann F. Der Fragebogen zur Lebensqualität bei Asthma und Chronisch-obstruktiver Bronchitis. In: Schumacher J, Klaiberg A, Brähler E (Hrsg). Diagnostische Verfahren zu Lebensqualität und Wohlbefinden. Göttingen: Hogrefe-Verlag 2003: 135-140
84 Juniper E F, Guyatt G H, Feeny D H. et al . Measuring quality of life in children with asthma. Qual Life Res. 1996; 5 35-46
85 Bateman E D, Boushey H A, Bousquet J. et al . Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170 836-844
86 Barnes N C. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med. 2004; 170 830-831
87 Platts-Mills T AE. Allergen avoidance in the treatment of asthma and rhinitis. N Engl J Med. 2003; 349 207-208
88 Platts-Mills T A, Tovey E R, Mitchell E B. et al . Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet. 1982; 2 675-678
89 Kerrebijn K F, Essen-Zandvliet E E, Neijens H J. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987; 79 653-659
90 Haahtela T, Järvinen M, Kava T. et al . Comparison of a β-2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991; 325 388-392
91 Barnes P J, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis. 1993; 148 S1-S26
92 Jeffery P K, Godfrey R W, Adelroth E. et al . Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis. 1992; 145 890-899
93 Djukanovic R, Wilson J W, Britten K M. et al . Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992; 145 669-674
94 Gardiner P V, Ward C, Booth H. et al . Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med. 1994; 150 1006-1011
95 Laitinen L A, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992; 90 32-42
96 Anderson S D, Rozea P J, Dolton R. et al . Inhaled and oral bronchodilator therapy in exercise induced asthma. Aust NZ J Med. 1975; 5 544-550
97 Shaw R J, Waller J F, Hetzel M R. et al . Do oral and inhaled terbutaline have different effects on the lung?. Br J Dis Chest. 1982; 76 171-176
98 Masoli M, Weatherall M, Beasley R. Optimal starting dose of inhaled corticosteroids in adult asthma: why has it taken so long?. Thorax. 2005; 60 93-94
99 Powell H, Gibson P G. Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review. Thorax. 2004; 59 1041-1045
100 Godfrey S, Bar-Yishay E. Exercised-induced asthma revisited. Respir Med. 1993; 87 331-344
101 Palmqvist M, Persson G, Lazer L. et al . Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997; 10 2484-2489
102 Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med. 1996; 334 1380-1388
103 Haahtela T, Järvinen M, Kava T. et al . Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994; 331 700-705
104 Simons F E. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med. 1997; 337 1659-1665
105 Lazarus S C, Boushey H A, Fahy J V. et al . Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001; 285 2583-2593
106 Lemanske R F, Sorkness C A, Mauger E A. et al . Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001; 285 2594-2603
107 Pauwels R A, Pedersen S, Busse W W. et al . Early intervention with budesonide in mild perisistent asthma: a randomised, double-blind trial. Lancet. 2003; 361 1071-1076
108 Powell H, Gibson P G. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust. 2003; 178 223-225
109 Wilson J W, Djukanovic R, Howarth P H. et al . Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med. 1994; 149 86-90
110 The Childhood Asthma Management Program Research Group . Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000; 343 1054-1063
111 Suissa S, Ernst P, Benayoun S. et al . Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343 332-336
112 Reed C E, Offord K P, Nelson H S. et al . Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. J Allergy Clin Immunol. 1998; 101 14-23
113 Evans D J, Taylor D A, Zetterström O. et al . A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997; 337 1412-1418
114 Tinkelman D G, Reed C E, Nelson H S. et al . Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics. 1993; 92 64-77
115 Ukena D, Harnest U, Sakalauskas R. et al . Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997; 10 2754-2760
116 Lim S, Jatakanon A, Gordon D. et al . Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax. 2000; 55 837-841
117 Busse W, Nelson H, Wolfe J. et al . Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol. 1999; 103 1075-1080
118 Nelson H S, Busse W W, Kerwin E. et al . Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol. 2000; 106 1088-1095
119 Fish J E, Israel E, Murray J J. et al . Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest. 2001; 120 423-430
120 Ringdal N, Eliraz A, Pruzinec R. et al . The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med. 2003; 97 234-241
121 Bjermer L, Bisgaard H, Bousquet J. et al . Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Br Med J. 2003; 327 891-895
122 Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med. 1998; 92 256-263
123 Shah L, Wilson A J, Gibson P G. et al . Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev. 2003; Issue 3 Art. No.: CD001281
124 Pauwels R A, Löfdahl C-G, Postma D S. et al . Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997; 337 1405-1411
125 Pearlman D S, Chervinsky P, LaForce C. et al . A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992; 327 1420-1425
126 Kesten S, Chapman K R, Broder I. et al . A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis. 1991; 144 622-625
127 Wenzel S E, Lumry W, Manning M. et al . Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol. 1998; 80 463-470
128 Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J. 2000; 320 1368-1373
129 Chapman K R, Ringdal N, Backer V. et al . Salmeterol and fluticasone propionate (50/250 µg) administered via combination diskus inhaler: as effective as when given via seperate diskus inhalers. Can Respir J. 1999; 6 45-51
130 Aubier M, Pieters W R, Schlosser N J. et al . Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med. 1999; 93 876-884
131 Bateman E. Salmeterol/fluticasone propionate combination. Drugs. 1999; 57 941-943
132 Berg N J van den, Ossip M S, Hederos C A. et al . Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol. 2000; 30 97-105
133 Nelson H S, Chapman K R, Pyke S D. et al . Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003; 112 29-36
134 Zetterström O, Buhl R, Mellem H. et al . Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001; 18 262-268
135 Cates C C, Bara A, Crilly J A. et al . Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2003; Issue 3 Art. No.: CD000052
136 Bisgaard H. A metal aerosol holding chamber devised for young children with asthma. Eur Respir J. 1995; 8 856-860
137 Williamson I J, Matusiewicz S P, Brown P H. et al . Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J. 1995; 8 590-592
138 Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax. 1991; 46 891-894
139 Brown P H, Greening A P, Crompton G K. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. Thorax. 1993; 48 233-238
140 Laviolette M, Malmstrom K, Lu S. et al . Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999; 160 1862-1868
141 Virchow J C, Prasse A, Naya I. et al . Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000; 162 578-585
142 Price D B, Hernandez D, Magyar P. et al . Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003; 58 211-216
143 Vaquerizo M J, Casan P, Castillo J. et al . Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003; 58 204-210
144 Persson G, Baas A, Knight A. et al . One month treatment with the once daily oral β2-agonist bambuterol in asthmatic patients. Eur Respir J. 1995; 8 34-39
145 Crompton G K, Ayres J G, Basran G. et al . Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am J Respir Crit Care Med. 1999; 159 824-828
146 Wallaert B, Brun P, Ostinelli J. et al . A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. Respir Med. 1999; 93 33-38
147 Greening A P, Ind P W, Northfield M. et al . Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994; 344 219-224
148 Woolcock A, Lundback B, Ringdal N. et al . Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996; 153 1481-1488
149 Busse W W, Chervinsky P, Condemi J. et al . Budesonide delivered by turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998; 101 457-463
150 Szefler S J, Martin R J, King T S. et al . Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002; 109 410-418
151 Lipworth B J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999; 159 941-955
152 Toogood J H, Baskerville J C, Jennings B. et al . Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol. 1982; 70 288-298
153 Rivington R N, Boulet L P, Cote J. et al . Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med. 1995; 151 325-332
154 Harrison B D, Stokes T C, Hart G J. et al . Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. Lancet. 1986; 1 181-184
155 O'Driscoll B R, Kalra S, Wilson M. et al . Double-blind trial of steroid tapering in acute asthma. Lancet. 1993; 341 324-327
156 Mash B, Bheekie A, Jones P W. Inhaled vs oral steroids for adults with chronic asthma. Cochrane Database Syst Rev. 2001; Issue 1 Art. No. CD002160
157 Dunlap N E, Fulmer J D. Corticosteroid therapy in asthma. Clin Chest Med. 1984; 5 669-683
158 Toogood J H, Baskerville J, Jennings B. et al . Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol. 1989; 84 688-700
159 American College of Rheumatology Task Force on Osteoporosis Guidelines . Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996; 39 1791-1801
160 Eastell R, Reid D M, Compston J. et al . A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998; 244 271-292
161 Otulana B A, Varma N, Bullock A. et al . High dose nebulized steroid in the treatment of chronic steroid- dependent asthma. Respir Med. 1992; 86 105-108
162 Hill J M. Nebulised corticosteroids in the treatment of patients with asthma. Thorax. 1999; 54 661-663
163 Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med. 2005; 11 27-34
164 Hill J M, Tattersfield A E. Corticosteroid sparing agents in asthma. Thorax. 1995; 50 577-582
165 Shiner R J, Nunn A J, Chung K F. et al . Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet. 1990; 336 137-140
166 Mullarkey M F, Lammert J K, Blumenstein B A. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med. 1990; 112 577-581
167 Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000; Issue 2 Art. No.: CD000391
168 Simon H U, Seelbach H, Ehmann R. et al . Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy. 2003; 58 1250-1255
169 Howarth P H, Babu K S, Arshad H S. et al . Tumour necrosis factor (TNF{alpha}) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005; 60 1012-1018
170 Lock S H, Kay A B, Barnes N C. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med. 1996; 153 509-514
171 Bernstein I L, Bernstein D I, Dubb J W. et al . A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol. 1996; 98 317-324
172 Nierop G, Gijzel W P, Bel E H. et al . Auranofin in the treatment of steroid dependent asthma: a double blind study. Thorax. 1992; 47 349-354
173 Aaron S D, Dales R E, Pham B. Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med. 1998; 92 1059-1065
174 Marin M G. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Chest. 1997; 112 29-33
175 Menz G, Buhl R, Gillissen A. et al . Schwieriges Asthma: Klinische Phänotypen und Prinzipien der Therapie. Pneumologie. 2002; 56 132-137
176 Ducharme F M. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br Med J. 2002; 324 1545-1551
177 Bleecker E R, Welch M J, Weinstein S F. et al . Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol. 2000; 105 1123-1129
178 Sharek P J, Bergman D A. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics. 2000; 106 E8
179 Tan S, Hall I P, Dewar J. et al . Association between beta-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997; 350 995-999
180 Martinez F D. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med. 2005; 353 2637-2639
181 Wechsler M E, Pauwels R, Drazen J M. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?. Drug Saf. 1999; 21 241-251
182 Wechsler M E, Finn D, Gunawardena D. et al . Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000; 117 708-713
183 Lilly C M, Churg A, Lazarovich M. et al . Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol. 2002; 109 S1-19
184 Newman S P. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med. 1995; 8 Suppl 3 S21-S26
185 Dolovich M. New delivery systems and propellants. Can Respir J. 1999; 6 290-295
186 Leach C L. Improved delivery of inhaled steroids to the large and small airways. Respir Med. 1998; 92 Suppl A 3-8
187 Harrison L I, Soria I, Cline A C. et al . Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol. 1999; 51 1235-1240
188 Agertoft L, Laulund L W, Harrison L I. et al . Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol. 2003; 35 192-199
189 Dewar A L, Stewart A, Cogswell J J. et al . A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital. Arch Dis Child. 1999; 80 421-423
190 Powell C V, Maskell G R, Marks M K. et al . Successful implementation of spacer treatment guideline for acute asthma. Arch Dis Child. 2001; 84 142-146
191 Matthys H. Praxis der Aerosoltherapie. In: Scheuch G (Hrsg). Aerosole in der Inhalationstherapie II. München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle 1998: 52-56
192 Gibson P G, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax. 2004; 59 94-99
193 Rodrigo G J, Castro-Rodriguez J A. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005; 60 740-746
194 Silverman R A, Osborn H, Runge J. et al . IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest. 2002; 122 489-497
195 Schuh S, Parkin P, Rajan A. et al . High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics. 1989; 83 513-518
196 Schuh S, Reider M J, Canny G. et al . Nebulized albuterol in acute childhood asthma: comparison of two doses. Pediatrics. 1990; 86 509-513
197 Robertson C F, Smith F, Beck R. et al . Response to frequent low doses of nebulized salbutamol in acute asthma. J Pediatr. 1985; 106 672-674
198 Schuh S, Johnson D W, Stephens D. et al . Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr. 1999; 135 22-27
199 Connett G J, Lenney W. Use of pulse oximetry in the hospital management of acute asthma in childhood. Pediatr Pulmonol. 1993; 15 345-349
200 Geelhoed G C, Landau L I, Le Souef P N. Evaluation of SaO₂ as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med. 1994; 23 1236-1241
201 Rowe B H, Spooner C H, Ducharme F M. et al . Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2001; Issue 1 Art. No. CD000195
202 Rowe B H, Spooner C, Ducharme F M. et al . Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2001; Issue 1 Art. No. CD002178
203 Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev. 2001; Issue 1 Art. No. CD001740
204 Becker J M, Arora A, Scarfone R J. et al . Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol. 1999; 103 586-590
205 Barnett P L, Caputo G L, Baskin M. et al . Intravenous versus oral corticosteroids in the management of acute asthma in children. Ann Emerg Med. 1997; 29 212-217
206 Langton H S, Hobbs J, Reid F. et al . Prednisolone in acute childhood asthma: clinical responses to three dosages. Respir Med. 1998; 92 541-546
207 Yung M, South M. Randomised controlled trial of aminophylline for severe acute asthma. Arch Dis Child. 1998; 79 405-410
208 Khine H, Fuchs S M, Saville A L. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med. 1996; 3 1019-1024
209 Papo M C, Frank J, Thompson A E. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med. 1993; 21 1479-1486
210 Travers A, Jones A P, Kelly K. et al . Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev. 2001; Issue 1 Art. No. CD002988
211 Plotnick L H, Ducharme F M. Acute asthma in children and adolescents: should inhaled anticholinergics be added to beta(2)-agonists?. Am J Respir Med. 2003; 2 109-115
212 Goodman D C, Littenberg B, O'Connor G T. et al . Theophylline in acute childhood asthma: a meta-analysis of its efficacy. Pediatr Pulmonol. 1996; 21 211-218
213 Parameswaran K, Belda J, Rowe B H. Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. Cochrane Database Syst Rev. 2000; Issue 4 Art. No. CD002742
214 Graham V, Lasserson T J, Rowe B H. Antibiotics for acute asthma. Cochrane Database Syst Rev. 2001; Issue 2 Art. No. CD002741
215 Fox G F, Marsh M J, Milner A D. Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. Eur J Pediatr. 1996; 155 512-516
216 Closa R M, Ceballos J M, Gomez-Papi A. et al . Efficacy of bronchodilators administered by nebulizers versus spacer devices in infants with acute wheezing. Pediatr Pulmonol. 1998; 26 344-348
217 Wildhaber J H, Devadason S G, Hayden M J. et al . Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol. 1997; 23 212-216
218 Rubilar L, Castro-Rodriguez J A, Girardi G. Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age. Pediatr Pulmonol. 2000; 29 264-269
219 Daugbjerg P, Brenoe E, Forchhammer H. et al . A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. Acta Paediatr. 1993; 82 547-551
220 Bentur L, Canny G J, Shields M D. et al . Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma. Pediatrics. 1992; 89 133-137
221 Prahl P, Petersen N T, Hornsleth A. Beta 2-agonists for the treatment of wheezy bronchitis?. Ann Allergy. 1986; 57 439-441
222 Tal A, Levy N, Bearman J E. Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial. Pediatrics. 1990; 86 350-356
223 Everard M L, Bara A, Kurian M. Anti-cholinergic drugs for wheeze in children under the age of two years. Cochrane Database Syst Rev. 2005; Issue 3 Art. No. CD001279
224 Schatz M, Harden K, Forsythe A. et al . The course of asthma during pregnancy, post partum, and with successive pregnancies: a prospective analysis. J Allergy Clin Immunol. 1988; 81 509-517
225 Murphy V E, Gibson P G, Smith R. et al . Asthma during pregnancy: mechanisms and treatment implications. Eur Respir J. 2005; 25 731-750
226 Stenius-Aarniala B S, Hedman J, Teramo K A. Acute asthma during pregnancy. Thorax. 1996; 51 411-414
227 Bergmann K-C. Spezifische Immuntherapie bei allergischem Asthma. Pneumologie. 2003; 57 84-90
228 Gillissen A, Bergmann K-C, Kleine-Tebbe J. et al . Die Bedeutung der spezifischen Immuntherapie beim allergischen Asthma bronchiale. Dtsch Med Wochenschr. 2003; 128 204-209
229 Buhl R, Beeh K M. Spezifische Immuntherapie bei Asthma bronchiale?. Pneumologie. 2003; 57 69-70
230 Kleine-Tebbe J, Fuchs T, Klimek L. et al . Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie, inhaltlich abgestimmt mit dem Ärzteverband Deutscher Allergologen. Pneumologie. 2001; 55 438-444
231 Bousquet J. Specific immunotherapy in asthma. Allergy. 1999; 54 Suppl 56 37-38
232 Bousquet J, Lockey R, Malling H J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998; 102 558-562
233 Abramson M J, Puy R M, Weiner J M. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003; Issue 4 Art. No. CD001186
234 Bousquet J, Michel F B, Malling H J. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized clinical trials. Am J Respir Crit Care Med. 1995; 152 1737-1738
235 Möller C, Dreborg S, Ferdousi H A. et al . Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002; 109 251-256
236 Pajno G B, Barberio G, De Luca F. et al . Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001; 31 1392-1397
237 Bousquet J, Michel F B. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf. 1994; 10 5-17
238 British Guideline on the Management of Asthma. Thorax. 2003; 58 Suppl 1 1-94
239 Gibson P G, Powell H, Coughlan J. et al . Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2002; Issue 1 Art. No. CD 001 117
240 Gibson P G, Powell H, Coughlan J. et al . Limited (information only) patient education programs for adults with asthma. Cochrane Database Syst Rev. 2002; Issue 1 Art. No. CD001005
241 Powell H, Gibson P G. Options for self-management education for adults with asthma. Cochrane Database Syst Rev. 2002; Issue 3 Art. No. CD004107
242 Petro W, Wettengel R, Worth H. Empfehlungen zum strukturierten Patiententraining bei obstruktiven Atemwegserkrankungen. Med Klin. 1995; 90 515-519
243 Ram F S, Robinson S M, Black P N. Physical training for asthma. Cochrane Database Syst Rev. 2005; Issue 4 Art. No. CD001116
244 Emtner M, Herala M, Stalenheim G. High-intensity physical training in adults with asthma. A 10-week rehabilitation program. Chest. 1996; 109 323-330
245 Worth H, Meyer A, Folgering H. et al . Empfehlungen der Deutschen Atemwegsliga zum Sport und körperlichen Training bei Patienten mit obstruktiven Atemwegserkrankungen. Pneumologie. 2000; 54 61-67
246 Holloway E, Ram F S. Breathing exercises for asthma. Cochrane Database Syst Rev. 2004; Issue 1 Art. No. CD001277
247 Thomas M, McKinley R K, Freeman E. et al . Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. Thorax. 2003; 58 110-115
248 Siroux V, Pin I, Oryszczyn M P. et al . Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J. 2000; 15 470-477
249 Ehrlich R I, Du T D, Jordaan E. et al . Risk factors for childhood asthma and wheezing. Importance of maternal and household smoking. Am J Respir Crit Care Med. 1996; 154 681-688
250 Panton J, Barley E A. Family therapy for asthma in children. Cochrane Database Syst Rev. 2000; Issue 2 Art. No. CD000089
251 American Thoracic Society . Pulmonary rehabilitation 1999. Am J Respir Crit Care Med. 1999; 159 1666-1682
252 Pulmonary rehabilitation. Thorax. 2001; 56 827-834
253 American College of Chest Physicians. American Association of Cardiovascular and Pulmonary Rehabilitation . Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. Chest. 1997; 112 1363-1396
254 Bergmann K C, Fischer J, Schmitz M. et al . Die stationäre pneumologische Rehabilitation für Erwachsene: Zielsetzung - diagnostische und therapeutische Standards - Forschungsbedarf. Pneumologie. 1997; 51 523-532
255 VDR Reha-Kommission: Kommission zur Weiterentwicklung der Rehabilitation in der gesetzlichen Rentenversicherung .Abschlussberichte - Band III, Teilband 2: Krankheitsspezifische Konzepte. Frankfurt: VDR 1991: 483-484
256 World Health Organisation .International Classification of Functioning, Disability and Health (ICF). 2001
257 Bundesversicherungsanstalt für Angestellte .Rehabilitationsbedürftigkeit und indikationsübergreifende Problembereiche - Leitlinien für den Beratungsärztlichen Dienst der BfA. 2002
258 Richtlinien des Gemeinsamen Bundesausschusses über Leistungen zur medizinischen Rehabilitation (Rehabilitations-Richtlinien) nach § 92 Abs. 1 Satz 2 Nr. 8 SGB V in der Fassung vom 16 März 2004. Bundesanzeiger. 2004; 63 6769
259 Cambach W, Wagenaar R C, Koelman T W. et al . The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis. Arch Phys Med Rehabil. 1999; 80 103-111
260 Cambach W, Chadwick-Straver R V, Wagenaar R C. et al . The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. Eur Respir J. 1997; 10 104-113
261 Bauer C P, Petermann F, Kiosz D. et al . Langzeiteffekt der stationären Rehabilitation bei Kindern und Jugendlichen mit mittelschwerem und schwerem Asthma bronchiale. Pneumologie. 2002; 56 478-485
262 Fischer J, Raschke F. Zielorientierte Messung von kurz-, mittel- und langfristigen Effekten in der pneumologischen Rehabilitation. Pneumologie. 2000; 54 458-463
263 Foglio K, Bianchi L, Bruletti G. et al . Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J. 1999; 13 125-132
264 Cox N J, Hendricks J C, Binkhorst R A. et al . A pulmonary rehabilitation program for patients with asthma and mild chronic obstructive pulmonary diseases (COPD). Lung. 1993; 171 235-244
265 de Vries U. Asthma - Patientenschulung im Rahmen ambulanter und stationärer Rehabilitation. Regensburg: Roderer Verlag 2004
266 Emtner M, Finne M, Stalenheim G. A 3-year follow-up of asthmatic patients participating in a 10-week rehabilitation program with emphasis on physical training. Arch Phys Med Rehabil. 1998; 79 539-544
267 Petermann F, Gulyas A, Niebank K. et al . Rehabilitationserfolge bei Kindern und Jugendlichen mit Asthma und Neurodermitis. Allergologie. 2000; 23 492-502
268 Worth H, Petro W. Vorschläge zu Struktur und Inhalten von Train-the Trainer-Seminaren für die Schulung von Patienten mit chronisch obstruktiven Atemwegserkrankungen. Pneumologie. 1998; 52 473-474
269 Spindler T, Rank M, Otto J. Veränderte psychosoziale Rahmenbedingungen erfordern Umdenken in der Rehabilitation. Kinder- und Jugendmedizin. 2001; 5 35-38
270 Pörings B, Spindler T. Elternschulung als Bestandteil der stationären Rehabilitation von Asthma. Kinder- und Jugendarzt. 2002; 33 473-476
271 Blanc P D, Toren K. How much adult asthma can be attributed to occupational factors?. Am J Med. 1999; 107 580-587
272 Balmes J, Becklake M, Blanc P. et al . American Thoracic Society Statement: Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med. 2003; 167 787-797
273 Mapp C E, Boschetto P, Maestrelli P. et al . Occupational asthma. Am J Respir Crit Care Med. 2005; 172 280-305
274 Nowak D. Chemosensory irritation and the lung. Int Arch Occup Environ Health. 2002; 75 326-331
275 Le Moual N, Siroux V, Pin I. et al . Asthma severity and exposure to occupational asthmogens. Am J Respir Crit Care Med. 2005; 172 440-445
276 Vandenplas O, Ghezzo H, Munoz X. et al . What are the questionnaire items most useful in identifying subjects with occupational asthma?. Eur Respir J. 2005; 26 1056-1063
277 Baur X, Haamann F, Heutelbeck A. et al . Arbeitsplatzbezogener Inhalationstest (AIT). Arbeitsmedizinische Leitlinien der Deutschen Gesellschaft für Arbeitsmedizin und Umweltmedizin. Arbeitsmedizin Sozialmedizin Umweltmedizin. 2005; 40 260-267
278 Nicholson P J, Cullinan P, Taylor A J. et al . Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med. 2005; 62 290-299

Univ.-Prof. Dr. med. R. Buhl

Schwerpunkt Pneumologie · III. Medizinische Klinik

Langenbeckstraße 1

55131 Mainz

Email: r.buhl@3-med.klinik.uni-mainz.de